Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an Outperform rating on Kiniksa Pharmaceuticals and raised the price target from $30 to $35.

October 30, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group has maintained an Outperform rating on Kiniksa Pharmaceuticals and increased the price target from $30 to $35, indicating positive expectations for the stock.
The increase in price target from $30 to $35 by Evercore ISI Group suggests a positive outlook for Kiniksa Pharmaceuticals. The Outperform rating indicates that the analyst expects the stock to perform better than the market average, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100